Download PDF
Zeitschrift für Orthomolekulare Medizin 2007; 5(2): 16-21
DOI: 10.1055/s-2007-965452
Anti-Aging

© Hippokrates Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG

Update Hormonersatz: Bioidentische Hormongaben sind risikoarm

Alexander Römmler
Further Information

Publication History

Publication Date:
21 August 2007 (online)

    Permissions and Reprints

Zusammenfassung

Die herkömmliche Hormonersatzherapie (HRT) aus oralen Östrogenen und synthetischen Progestagenen ist kurz- und langfristig risikobehaftet. Zur Risikoreduktion von Hormongaben sind vor allem die Wiederherstellung „natürlicher“ Hormonspiegel anzustreben. Dies gelingt durch die human-physiologischen Hormone 17β-Östradiol und Progesteron sowie eine jeweils geeignete Darreichung. Ein solcher „bioidentischer“ Hormonersatz ist an den genitalen und extragenitalen Zielorganen nebenwirkungsarm und wirkt sich günstig auf die Gesunderhaltung und Alterungsprävention aus.

Schlüsselwörter

Hormonersatztherapie - Prävention - Östradiol - Progesteron - bioidentisch

Literatur

  • 1 Bakken K, Alsaker E, Eggen A E, Lund E. Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer Study.  Int J Cancer. 2004;  112 (1) 130-134
    CrossrefGoogle Scholar
  • 2 Beral V. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study.  Lancet. 2003;  362 (9382) 419-427
    CrossrefGoogle Scholar
  • 3 Beral V, Bull D, Reeves G. Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study.  Lancet. 2005;  365 (9470) 1543-1551
    CrossrefGoogle Scholar
  • 4 Brincat M P. Hormone replacement therapy and the skin.  Maturitas. 2000;  35 (2) 107-117
    CrossrefGoogle Scholar
  • 5 Campagnoli C, Clavel-Chapelon F, Kaaks R. et al. . Progestins and progesterone in hormone replacement therapy and the risk of breast cancer.  J Steroid Biochem Mol Biol. 2005;  96 (2) 95-108
    CrossrefGoogle Scholar
  • 6 Canonico M, Straczek C, Oger E. et al. . Postmenopausal hormone therapy and cardiovascular disease: An overview of main findings.  Maturitas. 2006;  54 (4) 372-379
    CrossrefGoogle Scholar
  • 7 Chen W Y, Manson J E, Hankinson S E. et al. . Unopposed estrogen therapy and the risk of invasive breast cancer.  Arch Intern Med. 2006;  166 (9) 1027-1032
    CrossrefGoogle Scholar
  • 8 Clavel-Chapelon F, Fournier A. E3 N-EPIC cohort Update. Abstracts, 11th World Congress on the Menopause. Buenos Aires; Oct./2005 Buenos Aires
    Google Scholar
  • 9 Csizmadi I, Collet J P, Benedetti A. et al. . The effects of transdermal and oral oestrogen replacement therapy on colorectal cancer risk in postmenopausal women.  Br J Cancer. 2004;  90 (1) 76-81
    CrossrefGoogle Scholar
  • 10 De Lignieres B, Dennerstein L, Backstrom T .. Influence of route of progesterone metabolism.  Maturitas. 1995;  21 251-257
    CrossrefGoogle Scholar
  • 11 De Lignieres B, de Vathaire F, Fournier S. et al. . Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women.  Climacteric. 2002;  5 (4) 332-340
    Google Scholar
  • 12 Den Tonkelaar I, Oddens B J. Determinants of long-term hormone replacement therapy and reasons for early discontinuation.  Obstet Gynecol. 2000;  95 (4) 507-512
    CrossrefGoogle Scholar
  • 13 Dennison E M, Arden N K, Kellingray S. et al. . Hormone replacement therapy, other reproductive variables and symptomatic hip osteoarthritis in elderly white women: a case-control study.  Br J Rheumatol. 1998;  37 (11) 1198-1202
    CrossrefGoogle Scholar
  • 14 Dupont A, Dupont P, Cusan L. et al. . Comparative endocrinological and clinical effects of percutaneous estradiol and oral conjugated estrogens as replacement therapy in menopausal women.  Maturitas. 1991;  13 (4) 297-311
    CrossrefGoogle Scholar
  • 15 Fabre A, Fournier A, Mesrine S. et al. . Oral progestagens before menopause and breast cancer risk.  Br J Cancer. 2007;  96 (5) 841-844
    CrossrefGoogle Scholar
  • 16 Foidart J M, Colin C, Denoo X. et al. . Estradiol and progesterone regulate the proliferation of human breast epithelial cells.  Fertil Steril. 1998;  69 (5) 963-969
    CrossrefGoogle Scholar
  • 17 Fournier A, Berrino F, Riboli E. et al. . Breast cancer risk in relation to different types of hormone replacement therapy in the E3 N-EPIC cohort.  Int J Cancer. 2005;  114 (3) 448-454
    CrossrefGoogle Scholar
  • 18 Grodstein F, Lifford K, Resnick N M, Curhan G C. Postmenopausal hormone therapy and risk of developing urinary incontinence.  Obstet Gynecol. 2004;  103 (2) 254-260
    Google Scholar
  • 19 Grodstein F, Manson J E, Stampfer M J. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation.  J Womens Health (Larchmt). 2006 Jan;  15 (1) 35-44
    CrossrefGoogle Scholar
  • 20 Harvey P J, Morris B L, Miller J A, Floras J S. Estradiol induces discordant angiotensin and blood pressure responses to orthostasis in healthy postmenopausal women.  Hypertension. 2005;  45 (3) 399-405
    CrossrefGoogle Scholar
  • 21 Hendrix S L, Cochrane B B, Nygaard I E. et al. . Effects of estrogen with and without progestin on urinary incontinence.  JAMA. 2005;  293 (8) 935-948
    CrossrefGoogle Scholar
  • 22 Ho S M. Estrogen, progesterone and epithelial ovarian cancer.  Reprod Biol Endocrinol. 2003;  1 (1) 73-81
    CrossrefGoogle Scholar
  • 23 Huber J C. Hormonveränderungen im Alter: Genitale und extragenitale Auswirkungen.  Gynäkologe. 1996;  29 726-734
    Google Scholar
  • 24 Kirsh V, Kreiger N. Estrogen and estrogen-progestin replacement therapy and risk of postmenopausal breast cancer in Canada.  Cancer Causes Control. 2002;  13 (6) 583-590
    CrossrefGoogle Scholar
  • 25 Kovari E, Gold G, Herrmann F R. et al. . Cortical microinfarcts and demyelination significantly affect cognition in brain aging.  Stroke. 2004;  35 (2) 410-414
    CrossrefGoogle Scholar
  • 26 Lauritzen C. Die präventive Estrogen-Gestagen-Langzeitsubstitution.  Frauenarzt. 2001;  42 (11) 1230-1267
    Google Scholar
  • 27 Le Gal G, Gourlet V, Hogrel P. et al. . Hormone replacement therapy use is associated with a lower occurrence of carotid atherosclerotic plaques but not with intima-media thickness progression among postmenopausal women. The vascular aging (EVA) study.  Atherosclerosis. 2003;  166 (1) 163-170
    CrossrefGoogle Scholar
  • 28 Leake R. Contents of HRT and mechanisms of action.  J Epidemiol Biostat. 1999;  4 (3) 129-133
    Google Scholar
  • 29 Leo J C, Wang S M, Guo C H. et al. . Gene regulation profile reveals consistent anticancer properties of progesterone in hormone-independent breast cancer cells transfected with progesterone receptor.  Int J Cancer. 2005;  117 (4) 561-568
    CrossrefGoogle Scholar
  • 30 Micheli A, Muti P, Secreto G. et al. . Endogenous sex hormones and subsequent breast cancer in premenopausal women.  Int J Cancer. 2004;  112 (2) 312-318
    CrossrefGoogle Scholar
  • 31 Mosekilde L, Beck-Nielsen H, Sorensen O H. et al. . Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women - results of the Danish Osteoporosis Prevention Study.  Maturitas. 2000;  36 (3) 181-193
    CrossrefGoogle Scholar
  • 32 Moskowitz D. A comprehensive review of the safety and efficacy of bioidentical hormones for the management of menopause and related health risks.  Altern Med Rev. 2006 Sept;  11 (3) 208-223
    Google Scholar
  • 33 Nelson H D, Humphrey L L, Nygren P. et al. . Postmenopausal hormone replacement therapy: Scientific review.  JAMA. 2002;  288 (7) 872-881
    CrossrefGoogle Scholar
  • 34 Oelkers W K. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure.  Steroids. 1996;  61 (4) 166-171
    CrossrefGoogle Scholar
  • 35 O'Sullivan A J, Crampton L J, Freund J, Ho K KY. The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women.  J Clin Invest. 1998;  102 1035-1040
    Google Scholar
  • 36 Ohlinger R, Klein G M, Köhler G. et al. . Altersverteilung bei Patientinnen mit Mammatumoren in Abhängigkeit vom histologischen Befund.  Gyn. 2006;  11 110-116
    Google Scholar
  • 37 PEPI-Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.  JAMA. 1996;  275 (5) 370-375
    CrossrefGoogle Scholar
  • 38 Plu-Bureau G, Le M G, Thalabard J C. et al. . Percutaneous progesterone use and risk of breast cancer: results from a French cohort study of premenopausal women with benign breast disease.  Cancer Detect Prev. 1999;  23 (4) 290-296
    CrossrefGoogle Scholar
  • 39 Rabe T, Geisthövel F, Hadji P. et al. . Hormonersatztherapie - Nutzen und Risiken.  J Reproduktionsmed Endokrinol. 2006;  3 (3) 155-165
    Google Scholar
  • 40 Raine-Fenning N J, Brincat M P, Muscat-Baron Y. Skin aging and menopause: implications for treatment.  Am J Clin Dermatol. 2003;  4 (6) 371-378
    CrossrefGoogle Scholar
  • 41 Ridker P M, Rifai N, Rose L. et al. . Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.  N Engl J Med. 2002;  347 (20) 1557-1565
    CrossrefGoogle Scholar
  • 42 Römmler A. Paradigmenwechsel bei der Substitution mit Östrogenen.  ZS Orthomol Med. 2003;  3 13-17
    Google Scholar
  • 43 Römmler A. Neubewertung der HRT: Orale versus transdermale Östrogene sowie Progestagene versus Progesteron - Wege zur Risikoreduktion. Wolf A, Römmler A, Moltz L, Klentze M Anti Aging Medizin 2003. Berlin; Congress Compact Verlag 2004: 168-194
    Google Scholar
  • 44 Römmler A. Die Wahrheit über Hormone. München; Südwest 2006
    Google Scholar
  • 45 Römmler A. Endokrinologische Aspekte der Anti-Aging-Medizin.  CME Praktische Fortbildung Gynäkologie, Geburtsmedizin, Gynäkologische Endokrinologie. 2006;  3 18-34
    Google Scholar
  • 46 Römmler A. Wege zur risikoarmen HRT: Bioidentischer Hormonersatz.  J Preventive Medicine. 2007; 
    Google Scholar
  • 47 Rossouw J E, Anderson G L, Prentice R L. et al. . Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.  JAMA. 2002;  288 (3) 321-333
    CrossrefGoogle Scholar
  • 48 Rylance P B, Brincat M, Lafferty K. et al. . Natural progesterone and antihypertensive action.  Br Med J (Clin Res Ed). 1985;  290 (6461) 13-14
    Google Scholar
  • 49 Salpeter S R, Walsh J M, Greyber E. et al. . Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis.  J Gen Intern Med. 2004 Jul;  19 (7) 791-804
    CrossrefGoogle Scholar
  • 50 Scarabin P Y, Oger E, Plu-Bureau G. Estrogen and Thromboembolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk.  Lancet. 2003;  362 (9382) 428-432
    CrossrefGoogle Scholar
  • 51 Scarabin P Y. et al. .Abstracts, 11th World Congress on the Menopause. Buenos Aires; Oct./2005
    Google Scholar
  • 52 Schuback B. Die ältere Patientin im Brennpunkt der gynäkologischen Onkologie - demografische Entwicklung.  Gyn. 2006;  11 451-455
    Google Scholar
  • 53 Schumacher M, Guennoun R, Robert F. et al. . Local synthesis and dual actions of progesterone in the nervous system: neuroprotection and myelination.  Growth Horm IGF Res. 2004;  14 Suppl A S18-S33
    CrossrefGoogle Scholar
  • 54 Stahlberg C, Pedersen A T, Lynge E. et al. . Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe.  Int J Cancer. 2004;  109 (5) 721-727
    CrossrefGoogle Scholar
  • 55 Stefanick M L, Anderson G L, Margolis K L. et al. . WHI Investigators. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy.  JAMA. 2006;  295 (14) 1647-1657
    CrossrefGoogle Scholar
  • 56 Stephenson K, Price C, Kurdowska A. et al. . Progesterone cream does not increase thrombotic and inflammatory factors in postmenopausal women.  Blood. 2004;  104 116
    Google Scholar
  • 57 Straczek C, Oger E, Yon de Jonage-Canonico M B. et al. . Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration.  Circulation. 2005;  112 (22) 3495-3500
    CrossrefGoogle Scholar
  • 58 Tollan A, Oian P, Kjeldsen S E. et al. . Progesterone reduces sympathetic tone without changing blood pressure or fluid balance in men.  Gynecol Obstet Invest. 1993;  36 (4) 234-238
    Google Scholar
  • 59 Tsuda K, Kinoshita Y, Nishio I. Synergistic role of progesterone and nitric oxide in the regulation of membrane fluidity of erythrocytes in humans: an electron paramagnetic resonance investigation.  Am J Hypertens. 2002;  15 (8) 702-708
    CrossrefGoogle Scholar
  • 60 Vassilev V, Pretto C M, Cornet P B. et al. . Response of matrix metalloproteinases and tissue inhibitors of metalloproteinases messenger ribonucleic acids to ovarian steroids in human endometrial explants mimics their gene- and phase-specific differential control in vivo. J.  Clin Endocrinol Metab. 2005;  90 (10) 5848-5857
    CrossrefGoogle Scholar
  • 61 Von Muhlen D, Morton D, Von Muhlen C A, Barrett-Connor E. Postmenopausal estrogen and increased risk of clinical osteoarthritis at the hip, hand, and knee in older women.  J Womens Health Gend Based Med. 2002;  11 (6) 511-518
    CrossrefGoogle Scholar
  • 62 Vongpatanasin W, Tuncel M, Wang Z. et al. . Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women.  J Am Coll Cardiol. 2003;  41 (8) 1358-1363
    CrossrefGoogle Scholar
  • 63 Weiderpass E, Adami H O, Baron J A. et al. . Risk of endometrial cancer following estrogen replacement with and without progestins.  J Natl Cancer Inst. 1999;  91 (13) 1131-1137
    CrossrefGoogle Scholar
  • 64 Wolf A S. Progestagene sind nicht Progesteron. Römmler A, Wolf AS. Anti-Aging Sprechstunde, Teil 1: Leitfaden für Einsteiger. Berlin; Congress Compact Verlag 2002: 95-102
    Google Scholar

Privatdozent Dr. med. Alexander Römmler

Gynäkologische Praxisklinik, Hormonzentrum München

Westendstr. 193 - 195

80686 München

URL: http://www.hormonzentrum.de

    Literaturverzeichnis als PDF
>